

November 19, 2025

To,  
**National Stock Exchange of India Ltd.,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G-Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai-400051

**Scrip ID:** HVAX  
**Subject:** Clarification letter w.r.t. the Outcome of Board Meeting dated November 13, 2025  
**Reference:** Regulation 30 of the SEBI (LODR) Regulations, 2015

Dear Sir/ Madam,


Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform you that the Board has approved and took note the draft of the Term Sheet and Valuation Report for Potential Investment in Krew Instruments Private Limited, a Private Limited Company, operating in "Hospital Domain" by the Company in the board meeting dated November 13, 2025.

With respect to your email received on November 18, 2025, we are enclosing herewith the details of the above as prescribed under SEBI Listing Regulations as Annexure A.

Kindly take the same on your records.

Thanking You  
Yours faithfully,

For, **HVAX Technologies Limited**



**NRBHAYNARAYAN SUDARSHAN SINGH**  
Whole -time Director  
DIN: 02709947





**Annexure - A**

Sr. No.	Particulars	Details
A	Name of the target entity, details in brief such as size, turnover etc.;	Krew Instruments Private Limited FY 2025 annual turnover Rs. 2.61 crore with a PAT of 9%
B	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The target company is not a related party transaction
C	industry to which the entity being acquired belongs	Hospital & Laboratory segment
D	objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	<ul style="list-style-type: none"> <li>- Synergy</li> <li>- Cross selling opportunities</li> </ul> <p>Their offerings are a part of our customer's requirements</p>
E	brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
F	indicative time period for completion of the acquisition	Currently at evaluation phase – 6/8 months
G	consideration - whether cash consideration or share swap or any other form and details of the same	To be negotiated/decided
H	cost of acquisition and/or the price at which the shares are acquired	To be negotiated/decided
I	percentage of shareholding / control acquired and / or number of shares acquired	To be negotiated/decided
J	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p><b>Date of Incorporation:</b> 02/04/2018</p> <p><b>Registered Office:</b> Room No. 4/1101, Niraj Park, Wayle Nagar, Khadakpada, Thane, Kalyan, Maharashtra – 421301</p> <p><b>Promoters:</b></p> <ul style="list-style-type: none"> <li>• Biju Gopalkrishnan Unnithan</li> <li>• Bindu Biju Unnithan</li> </ul> <p><b>Product Lines:</b></p> <ul style="list-style-type: none"> <li>• Blood Bank Equipment</li> <li>• Pharma Equipment</li> <li>• Laboratory &amp; Healthcare Equipment</li> </ul>